Biotech Replimune's Q1 net loss widens, cash balance drops
RefinitivBacaan kurang dari 1 minit
Overview
Replimune fiscal Q1 net loss widens to $86.7 mln from $53.8 mln yr ago
Company's cash position decreased to $403.3 mln due to clinical development costs
Outlook
Replimune expects cash to fund operations into Q4 2026
Result Drivers
R&D EXPENSES - Increased due to scaling operations for RP1 commercial launch and higher personnel-related costs
SG&A EXPENSES - Rose significantly due to increased personnel and stock-based compensation costs
CASH DECREASE - Cash position fell due to clinical development costs and operating activities
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Net Income | -$86.69 mln | ||
Q1 Basic EPS | -$0.95 | ||
Q1 Cash & Investments | $403.30 mln | ||
Q1 Operating Expenses | $90.42 mln | ||
Q1 Operating Income | -$90.42 mln |
Press Release:
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini